Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 179.64M | 178.03M | 60.28M | 27.15M | 6.15M | 3.96M |
Gross Profit | 176.16M | 177.96M | 50.42M | -100.58M | -104.94M | -87.61M |
EBITDA | -52.48M | -52.66M | -128.20M | -155.59M | -155.68M | -125.81M |
Net Income | -69.89M | -70.81M | -113.87M | -165.46M | -158.09M | -130.09M |
Balance Sheet | ||||||
Total Assets | 158.07M | 245.96M | 282.62M | 328.92M | 469.55M | 451.14M |
Cash, Cash Equivalents and Short-Term Investments | 59.56M | 151.60M | 146.94M | 204.60M | 369.58M | 368.22M |
Total Debt | 23.30M | 74.21M | 25.23M | 23.08M | 25.47M | 23.71M |
Total Liabilities | 195.50M | 234.11M | 243.10M | 247.04M | 263.58M | 109.92M |
Stockholders Equity | -37.43M | 11.85M | 39.51M | 81.88M | 205.96M | 341.23M |
Cash Flow | ||||||
Free Cash Flow | -110.22M | -75.93M | -145.76M | -171.51M | 1.95M | -56.50M |
Operating Cash Flow | -107.86M | -73.21M | -140.88M | -141.77M | 10.73M | -53.59M |
Investing Cash Flow | -17.44M | -58.95M | 176.54M | 89.14M | 75.80M | -278.92M |
Financing Cash Flow | 24.19M | 78.75M | 880.00K | 12.87M | 3.29M | 340.05M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | HK$15.27B | 5.80 | -7.43% | 4.22% | 11.60% | -21.06% | |
49 Neutral | $87.15M | ― | -55.14% | ― | -99.43% | -69.40% | |
44 Neutral | $61.61M | ― | 91.63% | ― | -55.47% | 24.92% | |
41 Neutral | $59.80M | ― | -273.36% | ― | 883.05% | 62.93% | |
39 Underperform | $140.31M | ― | -73.85% | ― | ― | -40.59% | |
37 Underperform | $56.29M | ― | -55.59% | ― | ― | 65.02% | |
35 Underperform | $86.23M | ― | -101.34% | ― | ― | 21.40% |
Adaptimmune Therapeutics held its annual general meeting on May 29, 2025, where shareholders voted on several resolutions, including the re-election of directors and the approval of the company’s 2025 Employee and Non-Employee Share Option Schemes. The meeting also determined that advisory votes on executive compensation will be held annually until 2031, reflecting the company’s commitment to shareholder engagement and governance practices.
The most recent analyst rating on (ADAP) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Adaptimmune Therapeutics stock, see the ADAP Stock Forecast page.
Adaptimmune Therapeutics announced a variation to the previously agreed termination terms with their Chief Financial Officer, Gavin Wood. His employment will now end on August 31, 2025, due to redundancy, with severance terms including a 12-month salary, pro rata bonus eligibility, and healthcare benefits reimbursement.